Treatment with hydrogen-rich water protects against thioacetamide-induced hepatic encephalopathy in rats through stabilizing liver–brain disturbance
Wang X, Liu X, Zhou P, Feng J, Jia J, Xie B, Chen Y, Zhou J. · Scientific reports. 2025;15(1):17901.
What kind of evidence is this?
Preclinical
Controlled animal and cell study
Other neurological conditions
H₂-rich water
Not reported in this record.
Not reported in this record.
Methods at a glance
rats, rat, tissue, tissues used to study other neurological conditions.
Preclinical study; the full text reports 96 rats, with group/assay counts including n=24, n=8.
Multiple article-specific time points; see the linked full methods.
Full text reports H₂ dissolved in drinking water plus H₂ dissolved in saline. Detected intervention quantities or schedules: 5 ml/Kg, 10 ml/kg, 0.9%, 10 ml/Kg.
H₂ dissolved in drinking water plus H₂ dissolved in saline — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 5 ml/Kg, 10 ml/kg, 0.9%, 10 ml/Kg. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “The results showed that hydrogen-rich water can improve the behavioral changes of the HE rats, reduce blood ammonia, reduce liver function damage, alleviate the…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 40410340 · DOI: 10.1038/s41598-025-02891-2
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10